Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genetic Technologies ( (AU:GTG) ) has shared an update.
Genetic Technologies Limited has appointed Jeffrey Michael Le Compte and Campbell Welch as non-executive directors, effective 24 March 2026. These appointments signal a refresh of the company’s board, potentially bringing new oversight and strategic perspectives to its genetic testing and biotechnology operations.
At the same time, directors William Musgrave and Steven Nicols have resigned from the board as of 24 March 2026. The simultaneous additions and departures indicate a notable governance transition that may influence the company’s future direction, risk management, and engagement with investors and other stakeholders.
The most recent analyst rating on (AU:GTG) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Genetic Technologies stock, see the AU:GTG Stock Forecast page.
More about Genetic Technologies
Genetic Technologies Limited is an Australia-based company listed on the ASX under the ticker GTG. The firm operates in the biotechnology and genetics sector, with its activities focused on genetic testing and related technologies that support healthcare and diagnostics markets.
Technical Sentiment Signal: Sell
Current Market Cap: A$5.67M
See more data about GTG stock on TipRanks’ Stock Analysis page.